-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, multinational pharmaceutical giant GSK announced that it will spend US$1.
9 billion to acquire Sierra Oncology, a company that develops targeted therapy drugs for rare tumors, and at the same time it will acquire the core drug Momelotinib owned by the latter
.
According to public information, Momelotinib is a selective and highly oral bioavailability inhibitor of JAK1, JAK2 and ACVR1/ALK2, developed by Cytopia Inc in Australia.
Since the start of clinical trial research in 2009, more than 1,200 patients have received the drug.
Subjects were treated with this product, of which approximately 1000 patients were treated for myelofibrosis
.
Momelotinib is the first JAK inhibitor to show positive data on all key markers of disease symptoms, spleen response and anemia
.
It is worth mentioning that this medicine has a "frustrated" life experience and has changed hands 5 times
.
In 2009, Momelotinib was acquired by YM BioSciences, a Canadian biopharmaceutical company, for $14 million
.
In 2012, Gilead spent $510 million to acquire YM BioSciences and also owned Momelotinib
.
Gilead had high hopes for the drug, seeing it as a potential competitor to Incyte/Novartis' blockbuster JAK1/2 inhibitor ruxolitinib (Jakafi/Jakavi), hoping to make another breakthrough in the field of myelofibrosis and polycythemia vera city
.
However, in a phase III trial in 2016, Momelotinib was shown to be less effective than ruxolitinib in terms of secondary endpoints including total symptom scores, which also led Gilead to abandon further development
.
In August 2018, Gilead chose to sell Sierra Oncology at a low price, with a total price of $198 million, including milestones; the down payment was only $3 million
.
By April 2022, GSK announced that it would spend about US$1.
9 billion to acquire Sierra Oncology to supplement its own blood and tumor pipeline.
It is expected that new JAK drugs will be launched to the market in 2023
.
The transaction is expected to close on or before the third quarter of 2022
.
It is reported that the current phase III clinical trial of Momelotinib has been successful
.
In January 2022, the results of a pivotal phase 3 MOMENTUM clinical trial study in a global multicenter, randomized, double-blind study showed positive momentum, and Sierra Oncology plans to submit a New Drug Application (NDA) to the FDA in the second quarter of 2022 in the United States, the European Union Listing applications will be in the second half of 2022
.
The study is evaluating momelotinib in patients with myelofibrosis who are symptomatic and anemic and have been previously treated with an approved JAK inhibitor
.
Myelofibrosis is a rare hematological malignancy primarily caused by dysregulated JAK-STAT signaling, characterized by constitutional symptoms, splenomegaly, and progressive anemia
.
About half of myelofibrosis patients are known to experience moderate to severe anemia when eligible for JAK inhibitor therapy
.
If Momelotinib is successfully approved, it will bring a new treatment option to the majority of patients with myelofibrosis
.
In addition to the core product Momelotinib, ierra Oncology has two other Phase I drugs in development, namely the CHK1 inhibitor SRA737 licensed in 2016, and the BET inhibitor SRA5 from AstraZeneca
.
These product acquisitions will further expand GSK's backup drug pipeline and bring more possibilities for the company's future development
.
In recent years, under the reform of the pharmaceutical market, GSK has made frequent moves, including splitting the consumer health business to focus on its main business and acquiring innovative pharmaceutical companies
.
The 2021 financial report shows that the company's full-year turnover is 34.
114 billion pounds, in constant exchange rate (CER) terms (the same below), a year-on-year increase of 5%; adjusted earnings per share are 113.
2 pence, a year-on-year increase of 9%
.
Among them, the turnover of the consumer health department was 9.
607 billion pounds, an increase of 5% year-on-year
.
The company also said a new company spun off from the consumer healthcare unit, which owns brands including Panadol painkillers and Sensodyne toothpaste, is expected to go public in mid-2022
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
9 billion to acquire Sierra Oncology, a company that develops targeted therapy drugs for rare tumors, and at the same time it will acquire the core drug Momelotinib owned by the latter
.
According to public information, Momelotinib is a selective and highly oral bioavailability inhibitor of JAK1, JAK2 and ACVR1/ALK2, developed by Cytopia Inc in Australia.
Since the start of clinical trial research in 2009, more than 1,200 patients have received the drug.
Subjects were treated with this product, of which approximately 1000 patients were treated for myelofibrosis
.
Momelotinib is the first JAK inhibitor to show positive data on all key markers of disease symptoms, spleen response and anemia
.
It is worth mentioning that this medicine has a "frustrated" life experience and has changed hands 5 times
.
In 2009, Momelotinib was acquired by YM BioSciences, a Canadian biopharmaceutical company, for $14 million
.
In 2012, Gilead spent $510 million to acquire YM BioSciences and also owned Momelotinib
.
Gilead had high hopes for the drug, seeing it as a potential competitor to Incyte/Novartis' blockbuster JAK1/2 inhibitor ruxolitinib (Jakafi/Jakavi), hoping to make another breakthrough in the field of myelofibrosis and polycythemia vera city
.
However, in a phase III trial in 2016, Momelotinib was shown to be less effective than ruxolitinib in terms of secondary endpoints including total symptom scores, which also led Gilead to abandon further development
.
In August 2018, Gilead chose to sell Sierra Oncology at a low price, with a total price of $198 million, including milestones; the down payment was only $3 million
.
By April 2022, GSK announced that it would spend about US$1.
9 billion to acquire Sierra Oncology to supplement its own blood and tumor pipeline.
It is expected that new JAK drugs will be launched to the market in 2023
.
The transaction is expected to close on or before the third quarter of 2022
.
It is reported that the current phase III clinical trial of Momelotinib has been successful
.
In January 2022, the results of a pivotal phase 3 MOMENTUM clinical trial study in a global multicenter, randomized, double-blind study showed positive momentum, and Sierra Oncology plans to submit a New Drug Application (NDA) to the FDA in the second quarter of 2022 in the United States, the European Union Listing applications will be in the second half of 2022
.
The study is evaluating momelotinib in patients with myelofibrosis who are symptomatic and anemic and have been previously treated with an approved JAK inhibitor
.
Myelofibrosis is a rare hematological malignancy primarily caused by dysregulated JAK-STAT signaling, characterized by constitutional symptoms, splenomegaly, and progressive anemia
.
About half of myelofibrosis patients are known to experience moderate to severe anemia when eligible for JAK inhibitor therapy
.
If Momelotinib is successfully approved, it will bring a new treatment option to the majority of patients with myelofibrosis
.
In addition to the core product Momelotinib, ierra Oncology has two other Phase I drugs in development, namely the CHK1 inhibitor SRA737 licensed in 2016, and the BET inhibitor SRA5 from AstraZeneca
.
These product acquisitions will further expand GSK's backup drug pipeline and bring more possibilities for the company's future development
.
In recent years, under the reform of the pharmaceutical market, GSK has made frequent moves, including splitting the consumer health business to focus on its main business and acquiring innovative pharmaceutical companies
.
The 2021 financial report shows that the company's full-year turnover is 34.
114 billion pounds, in constant exchange rate (CER) terms (the same below), a year-on-year increase of 5%; adjusted earnings per share are 113.
2 pence, a year-on-year increase of 9%
.
Among them, the turnover of the consumer health department was 9.
607 billion pounds, an increase of 5% year-on-year
.
The company also said a new company spun off from the consumer healthcare unit, which owns brands including Panadol painkillers and Sensodyne toothpaste, is expected to go public in mid-2022
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
